2026 Q2 - tulosraportti
76 päivää sitten
‧43 min
4,00 SEK/osake
Viimeisin osinko
2,08%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 5 | ||
| 27 | ||
| 25 | ||
| 155 | ||
| 236 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 7.11.2025 | ||
2025 Q2 - tulosraportti 8.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
1 päivä sittenALL SOUNDS GOOD ACCORDING TO GEMINI Early indicators point to a strong rebound for the upcoming Q3 2026 results, which RaySearch is scheduled to publish on Tuesday, November 3, 2026. Key indicators and developments heading into the report include: * Timing Recoveries from Q2: Management noted in their Q2 interim report that several high-value transactions—particularly in the US—slipped past the mid-year cutoff into Q3. On August 10, RaySearch issued a dedicated update highlighting "strong order momentum in the USA at the start of the third quarter," confirming that those delayed orders had begun converting. * Reaffirmed Full-Year Margin Guidance: Despite softer license deliveries in the first half of the year, RaySearch reiterated its full-year 2026 target of an operating margin (EBIT) of at least 25%, signaling that management anticipates a heavy back-half earnings ramp. * Commercial Wins & Customer Expansions: Third-quarter contract activity included an order from the University of North Carolina School of Medicine for RayStation and an expansion agreement with Yonsei Cancer Center. * Strategic OEM Expansion: In September, RaySearch announced a major collaboration agreement with Accuray to integrate RayStation software directly into Accuray platforms for online adaptive radiotherapy, broadening their reach. * Pinnacle³ Migration Tailwinds: The ongoing phase-out of Philips Pinnacle³ continues to drive steady competitive replacement wins across North America and Europe into H2.
·13.8.I think the report was better than I had dared to hope for after the profit warning. Q2 was weak, but we already knew that. The important thing for me is that the order intake is strong and, above all, that several of the postponed US deals have actually come in at the beginning of Q3. This still supports the CEO's statement that the deals were delayed rather than lost. The fact that they also stick to a strong development in the second half of the year and the margin target of at least 25 % for 2026, I find positive. I'm staying put. Now it will be interesting to see if the US continues to deliver in Q3. With the share price around 195 kr, I still think RaySearch looks interesting in the slightly longer term.9.9.It is definitely the US market where the main risk resides. Trump being the buffoon throwing darts makes it extremely unsure.- ·10.8.I think RaySearch is starting to become really interesting again. After the profit warning, the big question was what had actually happened with the US business. Now it seems several new orders are coming from the USA, while the stock has recovered significantly from the bottom around 164 kr. It's certainly too early to say that everything is resolved, but it still lends some support to the CEO's message that the business has primarily been delayed and not lost. It will be interesting to see the report on Wednesday and especially what they say about the USA and the second half of the year. I think, in any case, that the case looks significantly better now than immediately after the profit warning.There might be some short covering from the short sellers now. New US orders and the price back above 190 kr make the situation a bit more uncomfortable for those who are short. It will be interesting to see what happens if the report also confirms that the US business has mostly been delayed. Regards
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
76 päivää sitten
‧43 min
4,00 SEK/osake
Viimeisin osinko
2,08%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 1 päivä sittenALL SOUNDS GOOD ACCORDING TO GEMINI Early indicators point to a strong rebound for the upcoming Q3 2026 results, which RaySearch is scheduled to publish on Tuesday, November 3, 2026. Key indicators and developments heading into the report include: * Timing Recoveries from Q2: Management noted in their Q2 interim report that several high-value transactions—particularly in the US—slipped past the mid-year cutoff into Q3. On August 10, RaySearch issued a dedicated update highlighting "strong order momentum in the USA at the start of the third quarter," confirming that those delayed orders had begun converting. * Reaffirmed Full-Year Margin Guidance: Despite softer license deliveries in the first half of the year, RaySearch reiterated its full-year 2026 target of an operating margin (EBIT) of at least 25%, signaling that management anticipates a heavy back-half earnings ramp. * Commercial Wins & Customer Expansions: Third-quarter contract activity included an order from the University of North Carolina School of Medicine for RayStation and an expansion agreement with Yonsei Cancer Center. * Strategic OEM Expansion: In September, RaySearch announced a major collaboration agreement with Accuray to integrate RayStation software directly into Accuray platforms for online adaptive radiotherapy, broadening their reach. * Pinnacle³ Migration Tailwinds: The ongoing phase-out of Philips Pinnacle³ continues to drive steady competitive replacement wins across North America and Europe into H2.
- ·13.8.I think the report was better than I had dared to hope for after the profit warning. Q2 was weak, but we already knew that. The important thing for me is that the order intake is strong and, above all, that several of the postponed US deals have actually come in at the beginning of Q3. This still supports the CEO's statement that the deals were delayed rather than lost. The fact that they also stick to a strong development in the second half of the year and the margin target of at least 25 % for 2026, I find positive. I'm staying put. Now it will be interesting to see if the US continues to deliver in Q3. With the share price around 195 kr, I still think RaySearch looks interesting in the slightly longer term.9.9.It is definitely the US market where the main risk resides. Trump being the buffoon throwing darts makes it extremely unsure.
- ·10.8.I think RaySearch is starting to become really interesting again. After the profit warning, the big question was what had actually happened with the US business. Now it seems several new orders are coming from the USA, while the stock has recovered significantly from the bottom around 164 kr. It's certainly too early to say that everything is resolved, but it still lends some support to the CEO's message that the business has primarily been delayed and not lost. It will be interesting to see the report on Wednesday and especially what they say about the USA and the second half of the year. I think, in any case, that the case looks significantly better now than immediately after the profit warning.There might be some short covering from the short sellers now. New US orders and the price back above 190 kr make the situation a bit more uncomfortable for those who are short. It will be interesting to see what happens if the report also confirms that the US business has mostly been delayed. Regards
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 5 | ||
| 27 | ||
| 25 | ||
| 155 | ||
| 236 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 7.11.2025 | ||
2025 Q2 - tulosraportti 8.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
76 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 3.11. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 7.11.2025 | ||
2025 Q2 - tulosraportti 8.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
4,00 SEK/osake
Viimeisin osinko
2,08%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- 1 päivä sittenALL SOUNDS GOOD ACCORDING TO GEMINI Early indicators point to a strong rebound for the upcoming Q3 2026 results, which RaySearch is scheduled to publish on Tuesday, November 3, 2026. Key indicators and developments heading into the report include: * Timing Recoveries from Q2: Management noted in their Q2 interim report that several high-value transactions—particularly in the US—slipped past the mid-year cutoff into Q3. On August 10, RaySearch issued a dedicated update highlighting "strong order momentum in the USA at the start of the third quarter," confirming that those delayed orders had begun converting. * Reaffirmed Full-Year Margin Guidance: Despite softer license deliveries in the first half of the year, RaySearch reiterated its full-year 2026 target of an operating margin (EBIT) of at least 25%, signaling that management anticipates a heavy back-half earnings ramp. * Commercial Wins & Customer Expansions: Third-quarter contract activity included an order from the University of North Carolina School of Medicine for RayStation and an expansion agreement with Yonsei Cancer Center. * Strategic OEM Expansion: In September, RaySearch announced a major collaboration agreement with Accuray to integrate RayStation software directly into Accuray platforms for online adaptive radiotherapy, broadening their reach. * Pinnacle³ Migration Tailwinds: The ongoing phase-out of Philips Pinnacle³ continues to drive steady competitive replacement wins across North America and Europe into H2.
- ·13.8.I think the report was better than I had dared to hope for after the profit warning. Q2 was weak, but we already knew that. The important thing for me is that the order intake is strong and, above all, that several of the postponed US deals have actually come in at the beginning of Q3. This still supports the CEO's statement that the deals were delayed rather than lost. The fact that they also stick to a strong development in the second half of the year and the margin target of at least 25 % for 2026, I find positive. I'm staying put. Now it will be interesting to see if the US continues to deliver in Q3. With the share price around 195 kr, I still think RaySearch looks interesting in the slightly longer term.9.9.It is definitely the US market where the main risk resides. Trump being the buffoon throwing darts makes it extremely unsure.
- ·10.8.I think RaySearch is starting to become really interesting again. After the profit warning, the big question was what had actually happened with the US business. Now it seems several new orders are coming from the USA, while the stock has recovered significantly from the bottom around 164 kr. It's certainly too early to say that everything is resolved, but it still lends some support to the CEO's message that the business has primarily been delayed and not lost. It will be interesting to see the report on Wednesday and especially what they say about the USA and the second half of the year. I think, in any case, that the case looks significantly better now than immediately after the profit warning.There might be some short covering from the short sellers now. New US orders and the price back above 190 kr make the situation a bit more uncomfortable for those who are short. It will be interesting to see what happens if the report also confirms that the US business has mostly been delayed. Regards
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 5 | ||
| 27 | ||
| 25 | ||
| 155 | ||
| 236 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt